Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 10, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 06, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 03, 2025 (GLOBE NEW ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NE ...

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm represents both individual and institutional investors in complex litigation across various courts [5]

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Company Background - Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs in the U.S. [1] - The lawsuit claims that Unicycive misrepresented the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) intended for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2]. - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. Group 2: Recent Developments - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party manufacturing vendor, which impacted discussions regarding the drug label [3]. - Following this announcement, Unicycive's stock price dropped over 40% [3]. - On June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA, further citing the cGMP deficiencies, leading to an additional stock price decline of nearly 30%, closing at $4.77 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Unicycive and can contact Robbins LLP to serve as lead plaintiff before the October 14, 2025 deadline [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged violations of federal securities laws during the Class Period from March 29, 2024, to June 27, 2025, related to misleading statements about the company's readiness for FDA compliance and the prospects of its New Drug Application for oxylanthanum carbonate [1][5]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court Northern District of California, seeking damages for all persons and entities that purchased Unicycive securities during the Class Period [1]. - Investors have until October 14, 2025, to request to be appointed as Lead Plaintiff for the class [2]. Group 2: Company Overview - Unicycive is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs, including oxylanthanum carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis [3]. Group 3: Allegations Against Defendants - Defendants allegedly made materially false and misleading statements regarding the company's business and compliance policies, overstating Unicycive's readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of the OLC NDA [5]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a significant stock price drop of 40.89% [6]. - Following the issuance of a Complete Response Letter (CRL) from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock price fell an additional 29.85% [7].

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from March 29, 2024, to June 27, 2025 [1][6]. Company Overview - Unicycive is a clinical-stage biotechnology company focused on developing therapies for unmet medical needs, including oxylanthanum carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis [4]. Legal Proceedings - The lawsuit seeks to recover damages for investors who purchased Unicycive securities during the Class Period, alleging that the company made materially false and misleading statements regarding its business and compliance policies [1][6]. - Investors have until October 14, 2025, to request appointment as Lead Plaintiff in the class action [2]. Regulatory Issues - Throughout the Class Period, Unicycive's management allegedly overstated the company's readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of the OLC New Drug Application (NDA) [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a significant drop in stock price by $3.68 per share (40.89%) [7]. - Following this, on June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA, further impacting the stock price, which fell by $2.03 per share (29.85%) [8].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in cGMP compliance at a third-party vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4][5]

Core Viewpoint - A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged violations of the Securities Exchange Act of 1934, specifically regarding misleading statements made by the company and its officers during the class period from March 29, 2024, to June 7, 2025 [1][2]. Company Summary - The lawsuit claims that Unicycive and certain officers made false and misleading statements about the company's readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its lead drug candidate, oxylanthanum carbonate (OLC) [2][4]. - Key events impacting the company's stock include: - Submission of the New Drug Application (NDA) for OLC to the FDA in September 2024 [4]. - Disclosure of deficiencies in cGMP compliance at a third-party manufacturing subcontractor on June 10, 2025, leading to a 40.9% stock drop to $5.32 [4]. - Issuance of a Complete Response Letter (CRL) by the FDA rejecting the OLC NDA due to cGMP issues on June 30, 2025, resulting in a further 29.9% stock decline to $4.77 [4]. - Investors must seek lead plaintiff appointment by October 14, 2025 [4].